Skip to main content

TVM Capital Life Science Leads €23 Million Series C Financing Round for Medical Reporting Technology Pioneer, Smart Reporting

Munich, Germany and Montreal, Quebec, Canada, April 22, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the successful closing of a €23 million Series C financing round for Smart Reporting, a pioneer and market leader in the field of medical reporting, particularly in radiology and pathology. TVM led the round, supported by Bayern Kapital and existing investors. The proceeds will be used primarily to expand international partnerships and product development and, in particular, to strengthen the company’s market presence in the US, Canada, Australia and New Zealand. Dr. Hubert Birner, Managing Partner at TVM, will join the Smart Reporting Board of Directors, and Stefan Fischer, Managing Partner (Finance), will serve as a Board Observer.

Medical documentation makes up to 40% of a physicians’ daily workload. Previously, this was mostly a manual process. Smart Reporting automates and streamlines this workflow and creates valuable data in the process; this is particularly important at a time when the number of radiologists is decreasing. The company’s groundbreaking medical documentation technology – “SmartReports” – delivers high-quality data in real-time and at any scale. This manufacturer-independent software offers a fully voice-controlled and data-driven documentation solution for doctors that forms the basis for workflow automation and machine-readable data. Smart Reporting thus provides a crucial module for digitalization in the hospital sector. In addition, Smart Reporting recently intensified its partnership with Solventum (formerly 3M Health Information Systems), one of the market leaders in the field of radiology reporting in North America, to further strengthen its presence in international markets. The collaboration provides customers access to additional cutting-edge technologies and innovation that will make radiology reporting even more time-efficient and data-driven. The software is distributed internationally via major healthcare IT partners, including Siemens Healthineers, GE Healthcare and Canon.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, said: “New technologies such as AI and machine learning are key drivers of innovation in the healthcare industry and offer great potential for growth. TVM sees Smart Reporting, with their groundbreaking technology, already used by thousands of doctors around the globe, as one of the future international market leaders in the areas of radiology and pathology. Also, the breadth of their partnerships with leading corporations in the radiology sector is impressive.”

“As an international venture capitalist in the life sciences, TVM finances innovative health tech and medical technologies in addition to traditional therapeutic drug development,” added Stefan Fischer, Managing Partner at TVM Capital Life Science. “The focus here is on differentiated business models of companies that are already commercially viable and create a direct benefit for patients with their technology. Smart Reporting fits perfectly into this investment strategy.”

Prof. Dr. Wieland Sommer, founder and Co-CEO of Smart Reporting, noted: “We are very pleased about the successful financing round and are grateful to TVM and our other investors for their strong support. With the additional capital, we will be able to consistently pursue our international growth strategy, which we recently launched with our market entry in the USA. Our focus in the coming months will be on further penetrating key global healthcare IT markets with our novel AI-based solutions.”

About Smart Reporting

Smart Reporting was founded in 2014 by Wieland Sommer, Professor of Radiology with a Master’s degree in public health (Harvard, US). The company was established in Munich with the vision of harnessing the value of medical data for better decision-making and treatment. Today, it has an interdisciplinary team of more than 80 doctors, data scientists and software engineers from Germany, Austria, Switzerland and Brazil who develop software based on their detailed understanding of clinical workflows. The company’s multilingual software for structured diagnostics in radiology and pathology is used by more than 16,000 physicians in over 90 countries. www.smart-reporting.com

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Contact:
TVM Capital Life Science

Dr. Hubert Birner, Managing Partner
Email: info@tvm-capital.com



 

 



Media Relations:
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
Email: tvm@mc-services.eu

North America: Laurie Doyle
Tel: +1 339 832 0752

 

 

 

TVM Capital Life Science to Participate in LSI USA ’24 Emerging MedTech Summit 2024

TVM and Portfolio Companies Showcase Transformative Partnerships and Industry Trends in Panel discussions and Presentations

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place March 18-22, 2024, in Dana Point, California, USA.  

“Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction. As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care. We look forward to engaging with fellow industry leaders at this year’s Emerging Medtech Summit and to exploring new opportunities with innovative entrepreneurs that could further enrich our portfolio,” said Dr. Luc Marengère, Managing Partner.

TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages TVM’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on innovative businesses from North America or the EU working to transform medical practice with their groundbreaking devices and technologies.

Dr. Sascha Berger, General Partner, emphasized: “Amidst the current hype surrounding artificial intelligence, it’s highly gratifying to participate in investments that embody the true transformative potential of AI in healthcare. These technologies have the capability to revolutionize how healthcare is delivered, making it accessible and personalized. Medtech and AI present exciting opportunities for investors who are willing to navigate this rapidly evolving landscape. Our successful track record of collaborations in medical technologies underscores our commitment to foster partnerships and add value to cutting edge innovative ventures.”

TVM Participation:

  • Luc Marengère – The End of One Road and the Beginning of Another: Transitioning from Pre to Post FDA
    March 20th | 5:10-5:50 pm PST | Track 2
  • Sascha Berger – Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?
    March 20th | 1:30-2:10 pm PST | Track 3

The following companies from TVM’s medtech commercial-stage portfolio will present at the summit:

  • Access Vascular, has developed and is commercializing award-winning intravenous catheters addressing the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade foreign body response and related complications.

  • Egg Medical, has developed and is commercializing a lab radiation protection system that dramatically reduces scatter radiation exposure during interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to anyone else in the room, resulting in an increased risk of cancer chromosomal abnormalities, skin damage and eye injury for healthcare professionals. EGGNEST™ reduces scatter radiation exposure by 91% for the entire team without interrupting the workflow.

  • Kent Imaging, develops, manufactures, and markets medical technology that supports real-time decision-making in wound care, vascular and surgical subspecialties and tracks the healing process. The company targets limb preservation and reconstructive surgical markets – areas with clear unmet need, as non-healing wounds are a major burden to patients and the healthcare system.

  • Vektor Medical, has developed and is commercializing an AI-based, non-invasive arrhythmia analysis technology, vMap, that enables physicians to pinpoint source locations rapidly and accurately for both focal and fibrillation-type arrhythmias. The company aims to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Contact:
TVM Capital Life Science

Dr. Luc Marengère, Managing Partner
Email: info@tvm-capital.com



 

 



Media Relations:
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
Email: tvm@mc-services.eu

North America: Laurie Doyle
Tel: +1 339 832 0752

 

 

 

TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care

Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology. TVM is co-leading the round with Solas BioVentures. The proceeds will be used to support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how electrophysiologists (EPs) approach ablation procedures. Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.

Vektor’s vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, seamlessly leveraging only a 12-lead ECG. vMap provides information to better understand arrhythmia source(s) enabling physicians to streamline their procedures and more efficiently treat their patients.

Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach. vMap has been embraced by EPs focused on excellence. With increased resources, Vektor will scale adoption across the US and Europe. Patients and healthcare providers deserve better and Vektor is ushering in that transition. We’re thrilled to invest and partner with Vektor to drive this important healthcare transformation.”

“The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical. “vMap presents a solution to this challenge. Leading EPs around the U.S. are utilizing vMap to streamline ablation procedures and improve patient outcomes. With the proceeds from this financing, we can expand access to this groundbreaking technology.”

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com

Follow Vektor Medical: LinkedIn and Twitter/X.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Contact:
TVM Capital Life Science

Dr. Luc Marengère, Managing Partner
Email: info@tvm-capital.com



 

 



Media Relations:
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
Email: tvm@mc-services.eu

North America: Laurie Doyle
Tel: +1 339 832 0752

 

 

 

TVM Capital Life Science Announces €8 Million Investment in myo to Revolutionize Elderly Care via Innovative, Easy-to-Use App

Munich, Germany and Montreal, Quebec, Canada (January 31, 2024) – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced the closing of a Series A financing round for Myosotis GmbH (“myo”), a pioneering Berlin-based digital healthcare startup. TVM led the round, investing €8 million. The proceeds will be used to further grow the business in the DACH region as well as in the UK. This will include expanding marketing capacity and enhancing service quality for existing customers, as well as developing new modules. Dr. Sascha Berger, General Partner, and Stefan Fischer, Managing Partner (Finance) of TVM, will join the myo Board of Directors.   

myo was founded in 2018 with the goal of relieving employees in care homes through digital solutions and bringing more transparency, participation and appreciation to the sector. The company’s communication app enables care facilities, families and service providers to communicate with each other easily, quickly and digitally. Families are able to participate in their loved ones’ everyday lives by receiving pictures, videos and documents as well as making video calls. Additional modules for the app simplify important but time-consuming administrative tasks, including ordering meals, monitoring complaints, and managing key external services such as laundry providers and pharmacies. This saves time and money and improves documentation. myo services approximately 400 customers in the DACH region and the UK.

Dr. Sascha Berger, General Partner of TVM Capital Life Science, commented: “At TVM, we are committed to advancing healthcare innovations that address unmet needs. Digital tools offer the promise of significantly increasing the efficiency of the healthcare system and giving medical professionals more time to do what they do best – care for their patients.  myo’s unique approach to elderly care communication could transform this crucial and growing sector, contributing to improved communication amongst healthcare staff, relatives and service providers, resulting in better care.”

Stefan Fischer, Managing Partner (Finance) of TVM Capital Life Science, noted: “The new digitalization strategy of Germany’s Ministry of Health not only acknowledges the incredible potential of digital solutions for the future of our under-pressure healthcare system, it also opens the way for groundbreaking technologies like myo’s apps to be integrated in a meaningful way into patient care. TVM is excited to see this important product rolled out in the DACH region and the UK. myo’s dynamic management team is well positioned to effectively scale myo’s innovative platform and make a tangible impact on the healthcare industry.”

Jasper Böckel, CEO of myo, added: “This funding is an important step in our growth plan. We are delighted to have such a well-regarded investor as TVM come on board and look forward to leveraging their experience with commercial-stage life science companies. Our passionate team is dedicated to enhancing human interactions in care settings, and these proceeds will now enable us to roll out our technology to more users and develop additional solutions for healthcare providers and families.”

About myo

Myosotis GmbH (Latin for forget-me-not flower) offers the first software-as-a-service solution for direct digital communication between employees, relatives and the ecosystem of service providers in care homes. The app enables intuitive communication with relatives through photos, videos, voice messages and video calls. This makes the impressive work in care more visible and simplifies administrative processes at the same time. The majority of communication – whether with relatives or third-party providers – can be handled by a single digital application. With just one click, homes can inform all relatives about new hygiene measures, for example, let a family participate in the life of the person in need of care and inform the doctor, pharmacy or external laundry service. This saves employees valuable time, which in turn can be used for caring for the elderly.

myo is already working with over 400 customers in DACH and the UK, including the most well-known providers, such as DRK, AWO, Johanniter and Agaplesion. Last year alone, over 30,000 users sent seven-figure interactions via the platform. In addition, interfaces have already been established with market leaders such as apetito, Sanacorp and CWS to further simplify communication for facilities.

In addition to new investors, TVM and Twip, existing shareholders include the nursing home operators Agaplesion and Carpe Diem, as well as the venture capital funds BonVenture, Axel Springer Plug & Play, Think Health, Mountain Partners, Round Hill Ventures and Capacura.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Contact:
TVM Capital Life Science
Dr. Sascha Berger, General Partner
Email: info@tvm-capital.com



 

 



Media Relations:
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
Email: tvm@mc-services.eu

North America: Laurie Doyle
Tel: +1 339 832 0752

 

 

 

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local treatment

Mage Biologics is the 10th early-stage or project focused company (PFC) investment for TVM Life Science Innovation II Fund

Montreal, Canada / Munich, Germany / Rheinfelden, Switzerland – 20 July 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma (“Tillotts”), today announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc. (“Mage Bio”). TVM will invest with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”) and will provide strategic advice to Mage Bio, with Dr. Sascha Berger, General Partner, joining the Board of Directors and Dr. Ivan Shaw, Principal, serving as a Board Observer. Mage Bio is the 10th early-stage or project-focused company (PFC) investment for TVM LSI II.

Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue penetration. The mAb has been developed by Tillotts and originated from a discovery collaboration with Swiss biotech company Numab Therapeutics. Utilizing Tillotts’ innovative sustained release approach, the antibody is designed to enable release of the drug in the appropriate area of the intestinal tract at a predetermined rate to address inflammation locally and optimally. Initially, the drug will be developed for the treatment of ulcerative colitis. Manufacturing of clinical-grade material is planned to start in 2023, with the goal of filing a clinical trial application in 2024.

Thomas A. Tóth von Kiskér, CEO and Board Director of Tillotts, commented: “We are excited to team up with TVM Capital Life Science to advance this oral antibody in ulcerative colitis, a lifelong disease profoundly impacting the patients’ quality of life. The collaboration with TVM underpins Tillotts’ leading role in developing and commercializing innovative products in the gastrointestinal field.”

“TVM Capital Life Science is proud to have enabled the creation of Mage Biologics. This investment is again a testament to our strong international network and builds on our successful single asset focus for innovative preclinical therapeutic agents,” said Sascha Berger, General Partner of TVM Capital Life Science and Member of the Board of Mage Biologics. “We are pleased to collaborate with the experienced management team of Johannes Spleiss and Chantal Miklosi, who will act as CEO and CFO, respectively, for Mage Biologics.”

Johannes Spleiss, Head of Scientific Affairs at Tillotts and CEO of Mage Biologics, added: “We are taking a new and potentially disruptive approach to overcome the challenges with traditional ulcerative colitis treatments with this oral antibody. Developing more efficacious therapies with a greater likelihood of success and less systemic side effects is an important step in continuing to innovate for the many patients living with this condition. I look forward to advancing our antibody to clinical proof of concept.”

About ulcerative colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that impacts millions of people worldwide. Ulcerative colitis affects the innermost lining of the colon and the rectum, causing inflammation and ulcers in the digestive tract. In most people, symptoms usually develop over time, taking a relapsing-remitting course, which means that periods of flare-ups are followed by periods of remission. This can be draining and, in some cases, lead to life-threatening complications. While there is no known cure, current treatments aim to reduce signs and symptoms of the disease and bring remission. Over the last decade, biologics have gained an important place in the treatment of ulcerative colitis, with several monoclonal antibodies available as subcutaneous or intravenous therapies approved for use in UC. Unfortunately, a substantial proportion of patients do not respond, lose response, or develop intolerance to currently marketed products, leading to a substantial unmet medical need for safer, effective, and more convenient therapeutic options.

About the project-focused company (PFC)
For its PFC investments, TVM has a unique arrangement with Eli Lilly and Company (“Lilly”), which is a limited partner in TVM LSI II and the earlier fund TVM LSI I, under which TVM and its PFCs have the option to engage Chorus, a full-service autonomous research and development unit within Lilly, to assist the PFC by implementing a lean and focused drug development plan, resulting in high-quality data packages to help determine proof of concept.

About Tillotts Pharma
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world. 

About TVM Capital Life Science
TVM Capital Life Science is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment.  This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About Mage Biologics Inc.
Mage Biologics is a special purpose company created to develop a novel, orally administered monoclonal antibody to clinical proof of concept for the treatment of ulcerative colitis. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma and is led by an experienced management team.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of gastrointestinal diseases that Mage Biologics Inc is developing. It reflects TVM’s current beliefs.

Media Relations

TVM
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Tillotts Pharma
Niclas Berg, Lead Corporate Communications
Phone: +46 722 48 46 26
Email: niclas.berg@tillotts.com

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Company highlights key investments from its commercial-stage medtech portfolio

Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs. One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care. In addition to connecting with fellow investors and dealmakers to discuss market opportunities and needs, we look forward to meeting young, highly innovative companies at the LSI Summit to further expand TVM’s strong medtech portfolio,” said Dr. Luc Marengère.

TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages TVM’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on innovative businesses from North America or the EU working to transform medical practice with their groundbreaking devices and technologies.

Dr. Sascha Berger added: “TVM’s track record of successful collaboration highlights our partnership and value-building approach with innovators. As true partners, we work closely with our portfolio companies, striving to understand their ideas, and find ways to advance their innovations to accelerate growth, facilitate market expansion and ultimately help them become or continue to be a leader in their respective markets. With our current fund TVM Life Science Innovation II, we continue to expand our strategy, that has been validated through a number of companies in both Fund I and II, to build a portfolio of differentiated products with strong leadership teams.”

Investment highlights from TVM’s medtech commercial-stage portfolio include:

  • Access Vascular Inc. has developed and commercializes award-winning intravenous catheters addressing the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade foreign body response and related complications.
  • Egg Medical has developed and commercializes a lab radiation protection system that dramatically reduces scatter radiation exposure during interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to anyone else in the room. This results in an increased risk of cancer chromosomal abnormalities, skin damage and eye injury for healthcare professionals in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the entire team without interrupting the workflow.
  • Emovi’s technologies and AI solutions address clinical challenges that exist through the continuum of care for patients with knee pain and pathology. The Company has developed the only FDA cleared, Health Canada licensed and CE Marked medical device to assess the 3D motion of the knee and understand what is happening in patient’s knee in order to better identify causes of symptoms and propose a successful care plan.
  • Kent Imaging, a leading innovator in near-infrared tissue oxygenation imaging, develops, manufactures, and markets medical technology that supports real-time decision-making in wound care, vascular and surgical subspecialties and tracks the healing process. Kent Imaging targets limb preservation and reconstructive surgical markets – areas with clear unmet need, as non-healing wounds are a major burden to patients and the healthcare system.
  • Panthera Dental, a world leader in CAD/CAM implant solutions and dental sleep appliances, has successfully combined creativity, science and know-how to bring to market its proprietary innovative technology to offer next-generation products to the dental industry as well as a novel innovation to treat sleep apnea. The Company just recently launched a new product: The Magnet-XTM, the world’s first removable magnetic implant bar offering stable forces, lateral guidance and stability and easy handling for patients with less dexterity.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The Company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies with commercial proof-of-concept as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Media Relations

MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752 Email: tvm@mc-services.eu

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

Montreal, Canada / Munich, Germany – 23 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the promotion of Dr. Valentina Agostoni and Catello Somma to Senior Associate and Philipp Lechner to Senior Associate Corporate Finance.

“I congratulate our three talented Senior Associates. We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions. It is gratifying to see each of them expand their roles in our team and take on increased responsibilities,“ said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, added: “These promotions underscore TVM’s commitment to professional development and talent recognition. Growing the next generation of leaders is an integral part of our strategy to position TVM for continued success. Each of these individuals brings different backgrounds, views and strengths to the team, which is essential to creating value for both our portfolio companies and investors.”

Valentina Agostoni, PhD joined TVM in December 2019, supporting the team in all stages of the investment process, particularly in deal flow screening and due diligence. Before joining TVM, she worked in preclinical development at Versantis AG and Mperia Therapeutics Inc, where she was involved in the clinical translation, from lead optimization to IND-enabling studies, of novel therapeutics across different disease areas. Valentina holds a Master’s degree in medical biotechnology from the University of Milano Bicocca and a PhD in biopharmacy and pharmaceutical technologies from the University of Paris-Saclay. She was the recipient of a Marie Curie ITN scholarship and conducted postdoctoral research in drug delivery and formulation at the Swiss Federal Institute of Technology Zurich (ETH-Zurich). She has co-authored several scientific articles and is co-inventor of 2 patents.

Catello Somma joined TVM in January 2020 and has played an integral role in deal flow generation and investment due diligence, as well as deal and exit transactions. Catello is a biotech start-up founder with more than ten years of clinical development and corporate development experience. Prior to this role, Catello worked for a mid-cap biotech where he supported the development of immuno-oncology assets, both internal and in partnership with big pharma, including the preparatory work for a successful licensing opportunity. Catello holds an MSc in molecular biology from the Università degli Studi di Napoli Federico II and an MBA with a major in finance, from MIP Politecnico di Milano.

Philipp Lechner joined TVM in July 2020. He is active in investment due diligence, deal and exit transactions as well as corporate finance and fund administration aspects of the fund. Prior to joining TVM, Philipp worked for the Global Healthcare Team at Société Générale Corporate & Investment Banking. In this role, he was involved in several cross-border M&A transactions in different healthcare industries. He holds a Master’s degree in international finance and economics from the Nuremberg Institute of Technology, with a focus on financial markets and corporate finance, and did additional business and finance studies in London, UK and Nuertingen, Germany.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Media Relations

MC Services AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

Montréal, Québec, February 21, 2023Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a follow-on investment by TVM Capital Life Science (“TVM”) through its fund TVM Life Science Innovation I SCSp and the Fonds de solidarité FTQ (the “Fonds”). Esperas is developing the first oral Check 1 inhibitor, ESP-001 (formerly LY2880070), a compound originally discovered through a research and development program at Eli Lilly and Company, with the potential to treat certain types of cancers including high-grade serous ovarian cancer (“HGSOC”).  

“The management team of Esperas is delighted to have the continued support of our original investors. The data generated to date combined with the advancing scientific knowledge support the continued development of this promising oral Check 1 inhibitor,” said Caroline Fortier, CEO of Esperas.

With these funds, Esperas will conduct a proof-of-concept study in a genetically selected sub-population of HGSOC. In a first proof-of-concept study in HGSOC, ESP-01, combined with low-dose gemcitabine, showed a significant rate of disease control (59.3%)1. This new trial will assess the efficacy of ESP-01 in combination with low-dose gemcitabine in patients with HGSOC with tumors expressing defined genetic profiles. The genetic assessments will be performed by Foundation Medicine through their Foundation One CDx test. Enrollment is expected to start in March 2023.

“Chk1 inhibition has a compelling rationale in this group of ovarian cancer patients with a high unmet medical need,” stated Dr. Wilson H. Miller, Director, Clinical Research Unit, Jewish General Hospital and a Principal Investigator in the study. “Initial data in ovarian cancer was very promising. Furthermore, there is no approved strategy for the treatment of ovarian cancer with the defined genetic signature in this study.”

“TVM is proud to continue its financial support of Esperas. The results generated in an initial proof-of-concept study in HGSOC show great promise for this unique anticancer agent,” said Dr. Luc Marengère, Managing Partner with TVM. “Furthermore, we are pleased to continue our collaboration with Caroline Fortier and Chantal Miklosi, who act as CEO and CFO, respectively, for Esperas.”

“This reinvestment demonstrates our commitment to finding a targeted treatment for ovarian cancer. The undertaking of clinical trials in Montréal, Toronto and Edmonton emphasizes our commitment to exploit the geographic expertise in order to improve patients’ lives everywhere. The Fonds de solidarité FTQ is proud to help Esperas in pursuing its goal of fighting one of the most life-threatening cancers in women’s health,” said Geneviève Guertin, Vice-President, Private Equity and Impact Investing, Life Sciences at Fonds de solidarité FTQ.

# # #

References

1ESMO 2022, Miller, W.H. et al. FPN # 537: A Phase 1b/2a Study of Oral Chk1 Inhibitor LY2880070 in Combination with Low-Dose Gemcitabine in Patients with Advanced Ovarian Cancer.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment. This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About the Fonds de solidarité FTQ

The Fonds de solidarité FTQ invests to build a better society by channeling the savings of its 753,125 shareholders into development and risk capital investments to help Québec transition to a green economy, to a human-centred world of work, and to a healthier society. The Fonds offers businesses unsecured financing and strategic support. With $17.8 billion in net assets as at November 30, 2022, the Fonds supported more than 3,600 partner companies and over 296,000 jobs.

About Esperas Pharma, Inc.

Esperas Pharma, Inc. is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation I and Fonds de solidarité FTQ (the “Fonds”). Esperas Pharma, Inc. is led by an experienced management team. The company has completed: 1) dose-escalations of ESP-001 monotherapy and in combination with gemcitabine; and 2) proof-of-concept trials in high-grade serous ovarian cancer and pancreatic cancer. A study assessing ESP-001 and low-dose gemcitabine in Ewing sarcoma is ongoing.

This press release contains forward-looking statements about TVM Life Science Innovation I SCSp investment in a clinical-stage compound for the treatment of certain types of cancers that is being developed by Esperas Pharma, Inc. It reflects TVM’s current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development. There is no guarantee that the product will receive regulatory approval, or if approved, would be commercially successful. TVM undertakes no duty to update forward-looking statements.

For additional information, please contact:

Caroline Fortier, CEO, Esperas Pharma, Inc.: esperas@mc-services.eu

Dr. Luc Marengère, Managing Partner, TVM Capital Life Science: marengere@tvm-capital.com, for media: TVM@mc-services.eu

Patrick McQuilken, Senior Advisor, Media Relations and Communications, Fonds de solidarité FTQ: pmcquilken@fondsftq.com

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund

Recurv is developing novel taxane, RP-001, against solid tumors

RP-001 delivered in nano-emulsion formulation, focusing drug delivery to tumor and sparing healthy organs

Strong efficacy in multiple pre-clinical cancer models, including multi-drug resistant tumors

 

Montreal, Canada / Munich, Germany – 01 February 2023 – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced that the company will invest up to USD 24 million in the newly formed U.S.-based biotechnology company, Recurv Pharma, Inc. (“Recurv”) with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”). Recurv plans to develop to proof-of-concept a novel taxane therapy to treat solid tumors. Also, TVM will provide strategic advice to the company with Dr. Luc Marengère, Managing Partner joining the Board of Directors and Dr. Valentina Agostoni, Associate, serving as a Board Observer.  Recurv is the 8th early-stage or project-focused company (PFC) investment for the TVM Life Science Innovation II Fund.

James E. Egan, CEO of Recurv, said: “TVM’s investment is designed to get us to a key value inflection point, namely, Phase 2a proof-of-concept, with our cancer program, RP-001. Taxanes have been a cornerstone of cancer treatment for decades, but they can come with significant side effects, and treated cancers frequently recur. We are looking to provide a safer, more efficacious treatment option that may be used in combination with immunotherapies and in a far wider range of cancers, even those resistant to current taxanes. We are excited to have TVM’s strong support and to now have the resources to further the development of this potentially game-changing molecule.”

Dr. Luc Marengère, Managing Partner of TVM, said: “TVM is excited about the potential of this novel approach which could introduce a new and safer taxane for cancers previously unresponsive to such treatment. Recurv is a perfect fit for TVM’s project-focused company investment objective – that is, to invest in first- or best-in-class product candidates with strong scientific rationale and the potential for clear differentiation from competition or added clinical value to current standard of care. TVM looks forward to working with James and the rest of the experienced team at Recurv to help them advance this important program into a clinical proof-of-concept.”

For its PFC investments, TVM has a unique arrangement with Eli Lilly and Company (“Lilly”), which is a limited partner in TVM LSI II and the earlier fund TVM LSI I, under which TVM and its PFCs have the option to engage Chorus, a full-service autonomous research and development unit within Lilly, to assist the PFC by implementing a lean and focused drug development plan, resulting in high-quality data packages to help determine proof of concept.

RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing healthy organs. The molecule has demonstrated the ability to kill tumors even in multi-drug resistant cancers, with strong efficacy in various pre-clinical tumor models, including non-small cell lung, breast, ovarian, prostate, pancreatic and colorectal cancers. It has also been proven in preclinical models to cure tumor types that are resistant to current taxane treatments. The data have shown that RP-001 can effectively kill cancer stem cells, the cells that trigger recurrence, and toxicology studies suggest a potentially superior safety profile compared to taxanes currently on the market. Additionally, RP-001 was demonstrated to be synergistic with immune checkpoint inhibitors in a pancreatic cancer model. 

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment.  This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc.

The TVM investment team has worked together for (over) a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About Recurv Pharma, Inc.

Recurv is a U.S.-based special purpose biotechnology company created to develop to clinical proof-of-concept one oncology compound, RP-001, a novel taxane therapy to treat solid tumors. The project is fully financed by TVM Life Science Innovation II. In various pre-clinical oncology models, the asset has shown strong efficacy data in addition to a potentially superior safety profile compared to currently available taxanes, as well as synergistic effects with immune checkpoint inhibitors.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of cancers that Recurv Pharma is developing. It reflects TVM’s current beliefs.

Contact

TVM Capital Life Science
Dr. Luc Marengère
Managing Partner
Email: marengere@tvm-capital.com

Media Relations

MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.

Auricula Biosciences plans to develop a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. This conjugate targets macropinocytosis, a unique feature of cancer cells harboring K-Ras mutations. The optimized molecule was subsequently developed at Syndivia.

Jean-Yves Bonnefoy, President of Syndivia and Member of the Board of Auricula Biosciences, commented: “We are very excited to team up with TVM Capital Life Science and its partner Eli Lilly and Company to advance this asset into Phase 1/2a human clinical trials. There are no approved treatments that target K-Ras mutations at large by this underlying mechanism of action, which we hope to address with our novel approach.”

Ivan Shaw, Ph.D., CEO of Auricula Biosciences said: “The management team of Auricula Biosciences is excited to have the opportunity to further develop, to clinical proof-of-concept, this promising asset with the potential to treat cancers characterized by K-Ras mutations. These malignancies remain a significant unmet clinical need to be addressed.”

Alain Thibault, MD., General Partner of TVM Capital Life Science, added: “TVM Capital Life Science is proud to have enabled the creation of Auricula Biosciences and to have secured the rights to a novel first-in-class asset that can positively impact challenging cancer indications. This investment is a testament to TVM’s transatlantic network and the single asset focus for innovative preclinical therapeutic agents.”

Luc Marengere Ph.D., Managing Partner of TVM Capital Life Science and Member of the Board of Auricula Biosciences, commented: “This is the seventh early-stage investment for TVM Life Science Innovation II, and TVM is pleased to collaborate with the well-proven management team of Ivan Shaw and Chantal Miklosi, who will act as CEO and CFO respectively for Auricula Biosciences.”

Auricula Biosciences plans to develop the first in class conjugate to a clinical proof-of-concept study in K-Ras mutant cancers. Ras mutation is the most frequent oncogenic alteration in human cancers. K-Ras is the most frequently mutated type and is found commonly in pancreas, colorectal, lung and urogenital cancers. The mutation confers a poor prognosis as current targeted therapies are effective in a minority of patients and hampered by the development of drug resistance. The conjugate to be developed by Auricula Biosciences has been designed to by-pass such resistance.

The global K-Ras Inhibitor Market Opportunity is projected to exceed US$1 Billion by 2025. Auricula Biosciences will seek clinical validation in various indications and may subsequently expand into others.

TVM Capital Life Science and Auricula Biosciences have the option to engage with Chorus, a full-service autonomous research and development unit within Lilly, to execute an efficient and cost-effective clinical plan.

About Syndivia
Syndivia is a company dedicated to deliver the best treatment to cancer patients by harnessing unique properties of tumor hallmarks and microenvironment promoting the development of innovative therapies for cancers with a high unmet medical need.

Syndivia

8 allée Gaspard Monge,

67083 Strasbourg, France

About TVM Capital Life Science
TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical, and medical technology industries with more than 30-years of transatlantic investment track record and over 1.4 USD billion raised and under management. With its investment teams located in North America and Europe, TVM Capital Life Science provides investors and entrepreneurs and innovation-seeking biopharmaceutical companies access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike.

The TVM Capital Life Science team looks back on more than 130 investments and over 90 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges. It has gained unrivaled international investment experience with its track record of dedicated board work, extensive global networks in life science research and product development, and direct knowledge of the local markets.

General Partner
TVM Life Science Innovation II (GP) S.a.r.l.
8, rue Lou Hemmer
L-1748 Senningerberg
Luxemburg

About Auricula Biosciences Inc.
Auricula Biosciences is a special purpose company created to develop one compound to clinical proof-of-concept. The project is fully financed by TVM Life Science Innovation II. The biopharmaceutical asset will enter toxicology studies and manufacturing in the next few months. Once cleared for clinical development by regulatory authorities, the Auricula Biosciences conjugate will be tested in patients with K-RAS mutant cancers to provide a clinical proof-of-concept of efficacy in this indication. Auricula Biosciences, Inc. is funded by TVM Life Science Innovation II and is led by an experienced management team.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of cancers that Auricula Biosciences Inc is developing. It reflects TVM’s current beliefs.

TVM Capital Life Science promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner

Munich, Germany / Montreal, Canada – 12 January 2022 – TVM Life Science (“TVM”),
a leading International Life Sciences Venture Capital firm, today announces the formal
promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner.  

Sascha has joined the TVM Capital Life Science team in 2016 as Principal and was
promoted to Partner in 2020. Sascha has more than 15 years professional experience.
He started his career as a management consultant at the Boston Consulting Group and later PricewaterhouseCoopers. He brings extensive experience in deal-making, life sciences venture capital, technology assessment and investment management with an academic background in chemistry and finance.

Alain joined the firm in 2020. He is a medical oncologist and an expert in first-in-man phase of oncology drug development. Prior to joining TVM, he held senior positions at Roche, Janssen, Regeneron and arGEN-X. His area of expertise includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies). His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science commented, “Sascha will continue to play a pivotal role in sourcing and managing new investment opportunities for the firm, both for early stage and late-stage opportunities. Sascha already built a strong network into the transatlantic biotech and investor community. We are very pleased to announce Sascha’s promotion to General Partner today.”

Dr. Luc Marengere, Managing Partner at TVM Capital Life Science added, “Alain is a highly respected and accomplished medical oncologist with a strong track record in late pre-clinical/early clinical development in oncology where TVM is currently focusing our early-stage Project Focused Company investment strategy in partnership with Eli Lilly & Company. We are delighted to promote Alain to General Partner.”

Stefan Fischer, Managing Partner (Finance) at TVM Capital Life Science stated, “We wish both new partners continued success as they assume their new leadership responsibilities. This is based on their proven achievements, their strong expertise as well as their commitment to the values of our firm. They reflect the broad spectrum of our talent and know-how along the investment value chain and the valuable contribution to TVM’s portfolio.”

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to international biopharmaceutical, medical technology, and diagnostic companies in North America and the EU. TVM follows a two-pronged strategy with a focus on early-stage and late-stage investments.

For more information please contact:

Stefan Fischer
Managing Partner (Finance), TVM Capital Life Science
fischer@tvm- capital.com
+49 89 998 992 36

 

Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases

Luxembourg, November 15th, 2021 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing T7 Therapeutics, Inc., a company based in Wilmington, Delaware, USA.

T7 Therapeutics plans to develop, a first-in-class monoclonal antibody targeting a broad set of autoimmune diseases to clinical proof-of-concept. This antibody targets a new critical pathway in autoimmunity, initially discovered by Nalân Utku during her training at the laboratories in Renal Division of Brigham and Women’s Hospital, Harvard Medical School. Humanized antibodies subsequently were developed at Nekonal S.a.r.l.

Nalân Utku, MD Ph.D. MDRA, CEO of Nekonal and Member of the Board of T7 Therapeutics, commented: “We are very excited to team up with TVM Capital Life Science and its partner Eli Lilly and Company to advance the chosen asset into human clinical trials. There are no approved treatments that specifically target this underlying mechanism of disease which we hope to address with our novel approach.”

Caroline Fortier, Ph.D., CEO of T7 Therapeutics said: “The management team of T7 Therapeutics is excited to have the opportunity to further develop, to clinical proof-of-concept, this promising asset with the potential to treat chronic inflammatory and autoimmune diseases. These diseases remain a significant unmet clinical need that needs to be addressed.”

Sascha Berger, Ph.D., General Partner of TVM Capital Life Science, added: “TVM Capital Life Science is proud to have enabled the creation of T7 Therapeutics and to have secured the rights to a novel first-in-class asset that can positively impact challenging indication targets. This investment is a testament to our transatlantic network and our single asset focus for innovative preclinical therapeutic agents.”

Marc Riviere, MD, CMO of TVM Capital Life Science and Member of the Board of T7 Therapeutics, commented: “This is the sixth early-stage investment for TVM Life Science Innovation II, and we are pleased to collaborate with the well-proven management team of Caroline Fortier and Mark Cipriano, who will act as CEO and CFO respectively for T7 Therapeutics.”

T7 Therapeutics plans to develop the first in class antibody to a proof-of-concept study in psoriatic arthritis. Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis — a disease that causes red patches of skin. Most people develop psoriasis years before being diagnosed with psoriatic arthritis. There is no cure for this disease. Treatment is aimed at controlling symptoms and preventing joint damage. Without treatment, psoriatic arthritis can be extremely painful and debilitating.

There are more than 80 different chronic inflammatory and autoimmune disorders, and the global autoimmune disease therapeutics market is projected to reach a value of more than 150 USD billion in 2025. T7 Therapeutics will seek clinical validation in psoriatic arthritis but may subsequently expand into various other indications.

TVM Capital Life Science and T7 Therapeutics have the option to engage with Chorus, a full-service autonomous research and development unit within Lilly, to execute an efficient and cost-effective clinical plan.

About Nekonal
Nekonal is a company dedicated to promoting the development of innovative therapies for the treatment and prevention of diseases with a high unmet medical need.

Nekonal S.a.r.l.

27-29, rue Henri Koch

LU-4354 Esch/Alzette

Luxembourg

About TVM Capital Life Science
TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical, and medical technology industries with more than 30-years of transatlantic investment track record and over 1.4 USD billion raised and under management. With its investment teams located in North America and Europe, TVM Capital Life Science provides investors and entrepreneurs and innovation-seeking biopharmaceutical companies access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike.

The TVM Capital Life Science team looks back on more than 130 investments and over 90 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges. It has gained unrivaled international investment experience with its track record of dedicated board work, extensive global networks in life science research and product development, and direct knowledge of the local markets.

General Partner
TVM Life Science Innovation II (GP) S.a.r.l.
8, rue Lou Hemmer
L-1748 Senningerberg
Luxemburg

About T7 Therapeutics Inc.
T7 Therapeutics is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II. To date, the biopharmaceutical asset has completed humanization and will enter GLP toxicology studies and manufacturing in the next few months. Once cleared for clinical development by regulatory authorities, the T7 Therapeutics antibody will be tested in healthy volunteers, and then in patients with psoriatic arthritis to provide a clinical proof-of-concept of efficacy in this indication. T7 Therapeutics, Inc. is funded by TVM Life Science Innovation II and is led by an experienced management team.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of auto-immune diseases that T7 Therapeutics Inc is developing. It reflects TVM’s current beliefs.

TVM Life Science Innovation II SCSp Announces Investment in Vespina Lifesciences Inc.

Luxembourg, February 1st, 2021 – TVM Life Science Innovation II SCSp today announced the Fund’s investment establishing Vespina Lifesciences Inc., a company based in Newark, Delaware.

Vespina Lifesciences Inc. plans to develop to proof-of-concept a potential best-in-class compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases.

The compound was originally discovered and characterized at Neuprozyme Therapeutics ApS. “Vespina Lifesciences Inc. is excited to have the opportunity to develop this promising candidate to clinical proof-of-concept in collaboration with TVM Capital Life Science. Pulmonary diseases are now at the forefront of significant unmet clinical needs which need to be rapidly addressed, and there is a critical need to develop meaningful treatments.

There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year, and this is likely significantly underrepresented, as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis.” said Ivan Shaw, CEO of Vespina Lifesciences Inc. “There are no approved treatments that specifically address the underlying mechanism of disease.”

“TVM Capital Life Science is proud to have enabled the creation of Vespina Lifesciences Inc., and to have secured the rights to a novel potential best-in-class asset that can positively impact challenging indication targets. This transaction is a testament to the benefits of our single asset and capital efficient investment model,” said Dr. Luc Marengere, Managing Partner with TVM Capital Life Science. “We are pleased to collaborate with Ivan Shaw and Chantal Miklosi, who will act as CEO and CFO respectively for Vespina Lifesciences Inc.”

This is the fifth early-stage investment for TVM Life Science Innovation II SCSp, a venture capital fund which follows a well-proven capital-efficient investment approach in developing pharmaceutical assets to human proof-of-concept in single-asset companies. Vespina Lifesciences Inc. will leverage its extensive product development expertise to potentially bring its asset to human proof-of-concept.

TVM Life Science Innovation II SCSp Announces Investment in Sarkana Pharma, Inc.

Luxembourg, February 1st, 2021 –TVM Life Science Innovation II SCSp today announced the fund’s investment establishing Sarkana Pharma, Inc., a company based in Wilmington, Delaware.

Sarkana Pharma, Inc. plans to develop, to proof-of-concept, an anti-inflammatory biologic with the potential to treat certain types of auto-immune diseases, including systemic lupus erythematosus (SLE).

This antibody targets a critical pathway in certain types of auto-immune diseases. It was originally discovered through one of Eli Lilly and Company’s (Lilly) research and development programs. “The management team of Sarkana Pharma, Inc. is excited to have the opportunity to further develop this promising agent for auto-immune disorders to clinical proof-of-concept in collaboration with the TVM Capital Life Science team. Auto-immune diseases, namely lupus, remain a significant unmet clinical need that needs to be addressed,” said Caroline Fortier, CEO of Sarkana Pharma, Inc.

Sarkana Pharma, Inc. plans to develop the antibody to a proof-of-concept study in systemic lupus erythematosus. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] Lupus strikes mostly women of childbearing age. However, men, children, and teenagers develop lupus, too. Ninety percent (90%) of people living with lupus are women. Most people with lupus develop the disease between the ages of 15-44.[2]

“TVM Capital Life Science is proud to have enabled the creation of Sarkana Pharma, Inc., and to have secured the rights to a biologic agent that aims to restore the body’s immune system’s equilibrium. This transaction is a testament to the benefits of our investment model,” said Dr. Luc Marengere, Managing Partner with TVM Capital Life Science. “Furthermore, we are pleased to collaborate with Caroline Fortier and Mark Cipriano, who will act as CEO and CFO respectively for Sarkana Pharma, Inc. Both have had a longstanding relationship with TVM and successful careers.”

This is the fourth early-stage investment for TVM Life Science Innovation II SCSp, a venture capital fund which follows a well-proven, capital-efficient investment approach to develop pharmaceutical assets to human proof-of-concept in single-asset companies. TVM Life Science Innovation II is a unique arrangement between TVM Capital Life Science and numerous limited partners, including Lilly. The goal is to finance and access innovation while managing risk and sharing reward.

Sarkana Pharma, Inc. will leverage its extensive product development expertise to potentially bring its asset to human proof-of-concept. “Early-stage investments by TVM Life Science Innovation II SCSp in project-focused companies such as Sarkana provide a capital-efficient method for developing potential new medicines in important therapeutic areas such as immunology,” said Kenneth Custer, Ph.D., Lilly’s vice president of corporate business development. “Lilly’s participation in the fund is one important way in which we collaborate with outside scientific teams to share risk and access promising external innovation.”

References
[1] GfK Roper. (2012). Lupus Awareness Survey for the Lupus Foundation of America [Executive Summary Report]. Washington, DC
[2] Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010 Feb;39(4):257-68. doi: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10. Review.


 

TVM Life Science Innovation II SCSp Announces Investment in ImmunoRx Pharma, Inc.

Luxembourg, January 19th, 2021TVM Life Science Innovation II SCSp today announced the fund’s investment establishing ImmunoRx Pharma, Inc., a company based in Wilmington, Delaware. ImmunoRx Pharma, Inc. plans to develop, to proof-of-concept, an anti-inflammatory biologic with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis and Crohn’s disease.  

This antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Philippe Tessier’s laboratory at Université Laval and Centre Hospitalier Universitaire (CHU) of Quebec. The intellectual property was subsequently licensed to InflammatoRx Inc. and humanized antibodies to the target were developed. “The management team of ImmunoRx Pharma, Inc. is excited to have the opportunity to further develop this promising anti-inflammatory agent to clinical proof-of-concept in collaboration with the TVM Capital Life Science team. Chronic inflammatory and auto-immune diseases remain a significant unmet clinical need that needs to be addressed,” said Caroline Fortier, CEO of ImmunoRx Pharma, Inc.

ImmunoRx Pharma, Inc. plans to develop the first in class antibody to a proof-of-concept study in ulcerative colitis. More than 11 million people worldwide are affected by inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood.

“TVM Capital Life Science is proud to have enabled the creation of ImmunoRx Pharma, Inc., and to have secured the rights to an anti-inflammatory biologic that aims to restore the body’s immune system’s equilibrium. This transaction is a testament to the benefits of our single asset and capital efficient investment model,” said Dr. Luc Marengere, Managing Partner with TVM Capital Life Science. “Furthermore, we are pleased to collaborate with Caroline Fortier and Mark Cipriano, who will act as CEO and CFO respectively for ImmunoRx Pharma, Inc. Both have had a longstanding relationship with TVM and successful careers.”

This is the third early-stage investment for TVM Life Science Innovation II SCSp, a venture capital fund which follows a well-proven capital-efficient investment approach in order to develop pharmaceutical assets to human proof-of-concept in single-asset companies.

ImmunoRx Pharma, Inc. will leverage its extensive product development expertise to potentially bring its asset to human proof-of-concept.

ImmunoRx Pharma, Inc.

ImmunoRx Pharma, Inc. is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II. To date, the biopharmaceutical asset has completed humanization and will enter GLP toxicology studies and manufacturing in the next few months. ImmunoRx Pharma, Inc. plans to begin clinical development by the end of 2022. Once cleared for clinical development by regulatory authorities, the ImmunoRx Pharma, Inc. biologic will be tested in healthy volunteers than in patients with ulcerative colitis with the goal of providing a clinical proof-of-concept of efficacy for IBD patients.  ImmunoRx Pharma, Inc. is funded by TVM Life Science Innovation II and is led by an experienced management team.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a pre-clinical stage compound for the treatment of certain types of inflammation and auto-immune diseases that is being developed by ImmunoRx Pharma Inc. It reflects TVM’s current beliefs.


Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp

CALGARY, AB, CANADA, January 13, 2021

/EINPresswire.com/ — Kent Imaging, an innovator in the tissue imaging market, announced today its partnership with TVM Life Science Innovation II SCSp to accelerate the global commercialization of its industry leading SnapshotNIR® product.

SnapshotNIR utilizes near infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Snapshot NIR assesses the microcirculation and conveys a comprehensive picture of tissue health and the healing capacity of wounds or surgical tissue. This FDA cleared, non-invasive approach to tissue assessment brings value to healthcare delivery in various clinical settings including wound care, plastic and reconstructive surgery, and vascular surgery.

“The confidence expressed by TVM in Kent’s products and technology reinforces our leadership in bringing innovation to this critical market. With this investment, Kent will expand on its product line, its partnerships and accelerate the introduction of this novel technology globally.” – Pierre Lemire, CEO Kent Imaging

“Kent Imaging commercializes innovative oxygenation imaging products targeting limb preservation and reconstructive surgical markets. This is an area with clear unmet need as non-healing wounds are a huge burden with respect to patient outcome and ever rising healthcare costs. TVM’s investment will further establish Kent Imaging on the global stage. We see Kent’s technology as the next major imaging modality and we are excited to be a part of the initiative to bring this technology to the global market. Kent Imaging will benefit from TVM Capital Life Science’s European and North American network to facilitate its market access abroad.” – Dr. Luc Marengere, Managing Partner, TVM Capital Life Science

In addition to the investment, Kent Imaging will also benefit with the addition of Dr. Luc Marengere and Dr. Alexandra MacLean, a Principal with TVM Capital Life Science, to its Board of Directors.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading innovator in oxygenation imaging, who develops, manufactures and markets medical technology that supports real-time decision making in wound care, vascular and surgical sub-specialties. Kent holds multiple patents in oxygen imaging technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally

TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history

  • The Fund continues the proven “Project Focused Company” investment strategy for early-stage drug development candidates.
  • In addition, the Fund continues to invest in late-stage clinical biopharmaceutical companies, medical device companies and diagnostic companies

Munich/Montreal: October 27, 2020 TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II). Committed capital totals US$478 million which was raised from high profile international investors, including Eli Lilly and Company, other strategic investors, pension funds, endowments, foundations, fund-of-funds, wealth managers and large US banks as well as multi and single family offices from the Americas, Europe and South Korea. The geographical focus for the Fund’s investment activity is on North-America and Europe.

TVM LSI II was substantially oversubscribed. The Fund already sold its first investment in February 2020.

TVM LSI II will maintain TVM’s focus on investing in assets that provide a visible and attractive exit strategy from the outset with the goal of maximizing returns and providing early and significant liquidity for its investors. About 50-60% of the Fund‘s capital is intended to be invested in “Project Focused Companies“ (“PFCs“) which are majority-owned by the Fund and set up for the development of early-stage drug candidates in a capital and time efficient manner. The remaining capital will be invested in late clinical stage biopharmaceutical companies as well as commercial stage medical device and diagnostic companies. The proven focus of TVM LSI II continues on building a portfolio of differentiated first-in-class and best-in-class assets that are diversified by indication and stage of development.

Dr. Luc Marengere, Managing Partner of TVM Capital Life Science commented: “We are thrilled by the strong support of existing and new investors in TVM LSI II. TVM LSI II is the largest fund raised by TVM since inception. In addition, we are grateful for the pivotal role in raising TVM LSI II in the Americas and Europe by New York based OCP and Founder Joelle Wyser-Pratte.”

Stefan Fischer, Managing Partner (Finance) stated: “We are confident that TVM LSI II will not only continue the TVM success story for our investors but will also enable the financing of the development of new and differentiated treatment options for patients with significant unmet medical needs.”

”The success of this fundraising effort is a strong validation of the innovative, capital-efficient investment strategy that we have implemented in 2012 together with Eli Lilly and Company. TVM LSI II intends to make investments in about 16 early-stage single asset PFCs and 10   late-stagecompanies with a focus on North America and Europe,” wrote Dr. Hubert Birner, Managing Partner of TVM Capital Life Science based in Munich.

With the closing of TVM LSI II, Stefan Fischer was promoted to Managing Partner (Finance) and Dr. Sascha Berger was promoted to Partner.

In the past few months, the TVM investment team was complemented with the addition of Alexandra McLean, MD and Alain Thibault, MD as Principals and, Dr. Valentina Agostina, Catello Somma and Philipp Lechner as Associates.

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to international biopharmaceutical, medical technology, and diagnostic companies in North America and the EU. TVM follows a two-pronged strategy with a focus on early and late stage investments.

www.tvm-lifescience.com.

Contacts:

Media/Press:

TVM Capital Life Science: Stefan Fischer, Managing Partner (Finance), TVM Capital Life Science: fischer@tvm- capital.com: +49 89 998 992 36

Investors:

OCP Capital: Joelle Wyser-Pratte, Founder,  joelle@ocpcap.com +1 914 441 3554